California Court orders in favor of Plexxikon in dispute with Novartis
Tokyo: Daiichi Sankyo has announced that the U.S. District Court for the Northern District of California has issued an order sustaining a jury verdict in favor of Plexxikon Inc. (its U.S. subsidiary whose offices closed in March 2022), on its claim that Novartis Pharmaceuticals Corporation's BRAF inhibitor Tafinlar infringes Plexxikon's U.S. Patents 9,469,640 and 9,844.539 ("the patents").
The case was filed by Plexxikon in August 2017. The order directs Novartis to pay $177.8 million in damages and a 9% royalty on U.S. sales of Tafinlar until the expiration of the patents of Plexxikon.
Read also: Novartis to take US drug patent case to Supreme Court
The Court reversed the jury's finding of willful infringement by Novartis. Any impact on Daiichi Sankyo's consolidated financials for fiscal year ending March 31, 2023, is currently being evaluated and will be announced as soon as possible.
